METHYS Dx is innovating for cancer patient monitoring through an ambitious R&D program, devised along the two folllowing axes :
- Discovery and characterization of new biomarkers for cancer patient monitoring
- Development of a disruptive, specific, ultrasensitive, and high-plex technology for molecular detection of such biomarkers.
Through the development of innovative products based on this R&D, METHYS Dx endeavours to transform patient monitoring, and by extension ensure better care of cancer patients.
Contact us for more information on our R&D program, and opportunities for partnership or collaboration with METHYS Dx!Contact Us